Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Specialties
Hematology
Oncology
Musculoskeletal Disorder
Rare Disease
Metabolic Disorder
Cardiovascular Disease
Ophthalmology
Neurology
Infectious Disease
View all Specialties
Technologies
Cell Therapy
MSC
iPSC
Gene Therapy
Genome Editing
Extracellular Vesicles
CAR-T Therapy
TCR Therapy
Tissue-Engineering & Biomaterials
View all Technologies
Topics
Treatment
Immuno-Oncology
Trial Updates
Perspectives
Manufacturing
COVID-19
View all Topics
Conferences
ASH 2022
TCT 2022
Meeting on the Med 2022
ICLE 2022
Advanced Therapies Week 2022
TERMIS 2021
ESGCT 2021
Meeting on the Mesa 2021
Advanced Therapies 2021
View all Conferences
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Leukemia
5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio
• 21 Feb 2023
3:52
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney
• 24 Feb 2023
3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Shah
• 15 Feb 2023
3:48
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML
Swati Naik
• 20 Feb 2023
8:25
CAR-T therapy in acute and chronic leukemias: current applications and future outlooks
John Gribben
• 10 Feb 2023
2:21
Exploring the potential role of CD7-targeting CAR-T cells in T-ALL
Maksim Mamonkin
• 10 Feb 2023
2:15
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner
• 10 Feb 2023
2:52
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01
David Sallman
• 11 Dec 2022
2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman
• 11 Dec 2022
3:58
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda
• 11 Dec 2022
5:09
Mechanisms of resistance to CAR T-cell therapies
John Rossi
• 26 Aug 2021
4:24
Chimeric engulfment receptor (CER) T-cell therapy
John Rossi
• 26 Jul 2021
2:17
Liquid vs solid tumor strategies in cell therapy
Kanya Rajangam
• 13 Oct 2021
1:51
Allogeneic NKX101 in liver cancer
Kanya Rajangam
• 13 Oct 2021
1:05
NKX019 in B-cell malignancies
Kanya Rajangam
• 13 Oct 2021
4:33
ISCT 2021 highlights: therapeutic deception, global regulation & CAR-T
Aaron Levine
• 28 May 2021
1
2
3
Next
